Association between plasma interleukin-18 levels and liver injury in chronic hepatitis C virus infection and non-alcoholic fatty liver disease

Annals of Clinical and Laboratory Science

Volumn 35, Issue 4, 2005, Pages 415-422

  Vecchiet, Jacopo ^a   Falasca, Katia ^a   Cacciatore, Pierluigi ^b   Zingariello, Pompea ^a   Dalessandro, Margherita ^a   Marinopiccoli, Marina ^a   D'Amico, Emilio ^b   Palazzi, Carlo ^b   Petrarca, Claudia ^a   Conti, Pio ^a   Pizzigallo, Eligio ^a   Guagnano, Maria Teresa ^a  

^a UNIVERSITY OF CHIETI   (Italy)

^b SPIRITO SANTO HOSPITAL   (Italy)

Author keywords

HCV infection; Interleukin 18; Non alcoholic fatty liver disease; Viral hepatitis

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ALPHA FETOPROTEIN; AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; BIOLOGICAL MARKER; CHOLESTEROL; FERRITIN; GAMMA GLUTAMYLTRANSFERASE; INTERLEUKIN 18; TRIACYLGLYCEROL;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BODY MASS; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; FERRITIN BLOOD LEVEL; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; HEPATITIS C; HUMAN; LIVER DISEASE; LIVER INJURY; MALE; NONALCOHOLIC FATTY LIVER; PRIORITY JOURNAL; TRIACYLGLYCEROL BLOOD LEVEL;

ALANINE TRANSAMINASE; ALKALINE PHOSPHATASE; BIOLOGICAL MARKERS; FATTY LIVER; FEMALE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERLEUKIN-18; LIVER; MALE; MIDDLE AGED;

HEPATITIS C VIRUS;

EID: 27644475534     PISSN: 00917370     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (43)

1. Schvoerer E, Navas MC, Thumann C, Fuchs A, Meyer N, Habersetzer F, Stoll-Keller F. Production of interleukin-18 and interleukin-12 in patients suffering from chronic hepatitis C virus infection before antiviral therapy. J Med Virol 2003;70:588-593.
2. Bouffard P, Hayashi PH, Acevero R, Levy N, Zeldis JB. Hepatitis C virus is detected in a monocyte/macrophage subpopulation of peripheral blood mononuclear cells of infected patients. J Infect Dis 1992;166:1276-1280.
3. Poynard T, Bedossa P, Opolon P for the OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups. Natural history of liver fibrosis progression in patients with chronic hepatitis C. Lancet 1997;349:825-832.
4. Sharara AI, Hunt CM, Hamilton JD. Hepatitis C. Ann Intern Med 1996;125:658-668.
5. Tarao K, Rino Y, Takemiya S, Tamai S, Ohkawa S, Sugimasa Y, Miyakawa K, Morinaga S, Yoshida M, Shibuya A, Kokubu S, Kakita A, Endo O. Close association between ligh serum ALT and more rapid recurrence of hepatocellular carcinoma in hepatectomized patients with HCV-associated liver cirrhosis and hepato-cellular carcinoma. Intervirol 2000;43:20-26.
6. Davis GL, Esteban-Mur R, Rustgi V, Hoefs J, Gordon SC, Trepo C, Shiffman ML, Zeuzem S, Craxì A, Ling MH, Albrecht J. Interferon alpha-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. International Hepatitis Interventional Therapy Group. NEJM 1998;339:1493-1499.
7. Conry-Cantilena C, VanRaden M, Gibble J, Menpolder J, Shakil AO, Viladomiu L, Cheung L, DiBisceglie A, Hoofnagle J, Shih JW. Routes of infection, viremia, and liver disease in blood donors found to have hepatitis C virus infection. NEJM 1996;334:1691-1696.
8. Puoti C. HCV carriers with persistently normal aminotransferase levels: normal does not always mean healthy. J Hepatol 2003;38:529-532.
9. National Institutes of Health Consensus Development Conference Panel. Management of hepatitis C. Hepatol 1997;26:S133-136.
10. EASL International Consensus Conference on Hepatitis C. Consensus statement. J Hepatol 1999;30:956-961.
11. Mathurin P, Moussali J, Cadranel JF, Thibault V, Charlotte F, Dumouchel P, Cazier A, Huraux JM, Devergie B, Vidaud M, Opolon P, Poynard T. Slow progression rate of fibrosis in hepatitis C virus patients with persistently normal alanine transaminase activity. Hepatology 1998;27:868-872.
12. Alberti A, Chemello L, Noventa F, Cavalletto L, De Salvo G. Therapy of hepatitis C: re-treatment with alpha interferon. Hepatology 1997;26:137S-142S.
13. Hoofnagle JH. Hepatitis C: the clinical spectrum of disease. Hepatology 1997;26:29S-33S.
14. Martinot-Peignoux M, Boyer N, Cazals-Hatem D, Pham BN, Gervais A, Le Breton V, Levy S, Degott C, Valla DC, Marcellin P. Prospective study of anti-hepatitis C virus-positive patients with persistently normal serum ALT with or without detectable serum HCV RNA. Hepatology 2001;34:1000-1005.
15. Persico M, Persico E, Suozzo R, Conte S, De Seta M, Coppola L, Palmentieri B, Sasso FC, Torella R. Natural history of hepatitis C virus carriers with persistently normal aminotransferase levels. Gastroenterology 2000;118:760-764.
16. Jamal MM, Soni A, Quinn PG, Wheeler DE, Arora S, Johnston DE. Clinical features of hepatitis C-infected patients with persistently normal alanine transaminase levels in the southwestern United States. Hepatology 1999;30:1307-1311.
17. Ghoulson CF, Morgan K, Catinis G, Favrot D, Taylor B, Gonzalez E, Balart L. Chronic hepatitis C with normal aminotransferase levels: a clinical histologic study. Am J Gastroenterol 1997;92:1788-1792.
18. Alberti A, Noventa F, Benvegnu L, Boccato S, Gatta A. prevalence of liver disease in a population of asymptomatic persons with hepatitis C virus infection. Ann Intern Med 2002;137:961-964.
19. Puoti C, Stati T, Magrini A, Rigato P, Romagnoli G, Rossi P, Montagnese F, Resta S. Liver histology in anti-HCV positive subjects with normal ALT levels. Ital J Gastroenterol Hepatol 1997;29:383-384.
20. Kyrlagkitsis I, Portmann B, Smith H, O'Grady J, Cramp M. Liver histology and progression of fibrosis in individual with chronic hepatitis C and persistently normal ALT. Am J Gastroenterol 2003;98:1588-1593.
21. Puoti C, Guido M, Mangia A, Persico M, Prati D. Clinical management of HCV carriers with normal aminotransferase levels. Digest Liver Dis 2003;35:362-369.
22. Cairns W, Smith CA, McLaren AW, Wolf CR. Characterization of the human cytochrome P4502D6 promoter. A potential role for antagonistic interactions between members of the nuclear receptor family. J Biol Chem 1996;271:25269- 25276.
23. Angulo P, Alba LM, Petrovic LM, Adams LA, Lindor KD, Jensen MD. Leptin, insulin resistance, and liver fibrosis in human nonalcoholic fatty liver disease. J Hepatol 2004;42:943-949.
24. Schirren CA, Jung MC, Gerlach JT, Worzfeld T, Baretton G, Mamin M, Hubert Gruener N, Houghton M, Pape GR. Liver-derived hepatitis C virus-specific CD4+ T cells recognize multiple HCV epitopes and produce interferon gamma. Hepatology 2000;32:597-603.
25. Marinos G, Rossol S, Carucci P, Wong PY, Donaldson P, Hussain MJ, Vergani D, Portmann BC, Williams R, Naoumov NV. Immunopathogenesis of hepatitis B virus recurrence after liver transplantation. Transplantation 2000;69:559-568.
26. Woitas RP, Rockstroh JK, Beier I, Jung G, Kochan B, Matz B, Brackmann HH, Sauerbruch T, Spengler U. Antigen-specific cytokine response to hepatitis C virus core epitopes in HIV/hepatitis C virus-coinfected patients. AIDS 1999;13:1313-1322.
27. Lebel-Binay S, Berger A, Zinzindohoue F, Cugnenc P, Thiounn N, Fridman WH, Pages F. Interleukin-18: biological properties and clinical implications. Eur Cytokine Netw 2000;11:15-26.
28. Dinarello CA. Interleukin-18, a proinflammatory cytokine. Eur Cytokine Netw 2000;11:483-486.
29. McGuinness PH, Painter D, Davies S, McCaughan GW. Increases in intrahepatic CD68 positive cells, MAC387 positive cells, and proinflammatory cytokine (particularly interleukin 18) in chronic hepatitis C infection. Gut 2000;46:260-269.
30. Kaser A, Novick D, Rubinstein T, Siegmund B, Enrich B, Koch RO, Vogel W, Kim SH, Dinarello CA, Tilg H. Interferon-alpha induces interleukin-18 binding protein in chronic hepatitis C patients. Clin Exp Immunol 2002;129:332-336.
31. Jia H, Du J, Zhu S, Ma Y, Cai H. Clinical observation of serum IL-18, IL-10 and sIL-2R levels in patients with chronic hepatitis C pre-and post antiviral treatment. Clin Med J 2003;116:605-608.
32. Knodell RG, Ishak KG, Black WC, Craig R, Kaplowitz N, Kiernan TW, Wollman J. Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. Hepatology 1981;1:431-435.
33. Pileri P, Uematsu Y, Campagnoli S, Galli G, Falugi F, Petracca R, Weiner AJ, Houghton M, Rosa D, Grandi G, Abrignani S. Binding of hepatitis C virus to CD81. Science 1998;282:938-941.
34. Bertoletti A, D'Elios MM, Boni C, De Carli M, Zignego AL, Durazzo M, Missale G, Penna A, Fiaccadori F, Del Prete G, Ferrari C. Different cytokine profile of intrahepatic T cells in chronic hepatitis B and hepatitis C virus infection. Gastroenterology 1997;112:193-199.
35. Sobue S, Nomura T, Ishikawa T, Ito S, Saso K, Ohara H, Joh Titoh M, KaKumu S. Th1/Th2 cytokine profiles and their relationship to clinical features in patients with chronic hepatitis C virus infection. J Gastroenterol 2001;36:544-551.
36. Fan XG, Liu WE, Li CZ, Wang ZC, Luo LX, Tan DM, Hu GL, Zhang Z. Circulating Th1 and Th2 cytokines in patients with hepatitis C virus infection. Mediators Inflamm 1998;7:295-297.
37. Boni C, Amadei A, Urbani S, Fisicaro P, Zerbini A, Mori C, Missale G, Bertoni R, Azzurri A, Del Prete G, Ferrari C. Antiviral CD8-mediated responses in chronic HCV carriers with HBV superinfection. Hepatology 2004;40:289-299.
38. Zhang Y, Wang Y, Gilmore X, Xu K, Mbawuike IN. Independent and synergistic effects of interleukin-18 and interleukin-12 in augmenting cytotoxin T lymphocyte responses and IFN-gamma production in aging. J Interferon Cytokine Res 2001;21:843-850.
39. Kempuraj D, Frydas S, Karagouni E, Hatzstilianou M, Boscolo P, Ferro F, Di Giannantonio M, Conti CMV, Merlitti D, Doyle R, Petrarca C, Castellani M, Theoharides TC. Cytokines and the brain. Int J Immunopathol Pharmacol 2004;17:229-232.
40. De Lutiis MA, Felaco M, Gizzi F, Patruno A, Sperana L, Di Giulio C, Conti P, Castellani ML, Grilli A. A scavenger role of nitric oxide in the aged rat kidney. Int J Immunopathol Pharmacol 2004;17:265-271.
41. Kempraj D, Donelan J, Frydas S, Iezzi T, Conti P, Boucher W, Papadoopoulou NG, Madhappan B, Letourneau L, Sabatino G, Riccioni G, Theoharides TC. Interleukin-28 and 29 (IL-28 and IL-29): new cytokines with antiviral activities. Int J Immunopathol Pharmacol 2004;17:103-106.
42. Marra F. NASH: are genes blowing the hits? J Hepatol 2004;40:853-856.
43. Kugelmas M, Hill DB, Vivian B, Marsano L, McClain CJ. Cytokines and NASH: a pilot study of the effects of lifestyle modification and vitamin E. Hepatology 2003;38:413-419.